Skip to content Skip to footer
Subscribe Now
A Complete Account of EMA Approvals in 2023
INSIGHTS+

A Complete Account of EMA Approvals in 2023

Shots:  In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology  PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology  For…
March 5, 2024

Read more

VIEWPOINTS_Eli Khankin_2023
VIEWPOINTS

Eli Khankin Shares Update on the P-III IMAGINE Study Protocol Published in American Journal of Transplantation

Shots: Eli spoke about the P-III IMAGINE study protocol evaluating Clazakizumab along with 6 articles by several experts published in the American Journal of Transplantation Eli then talked about Clazakizumab's potential mechanism of action currently under investigation The interview shows how CSL Behring works to develop and deliver innovative therapies for people living with conditions in…
August 31, 2023

Read more

VIEWPOINTS_Tahi Ahmadi1_Asud Khaliq2_2023
VIEWPOINTS

Tahi Ahmadi and Asud Khaliq Share their Views on EPKINLY (epcoritamab) U.S. FDA Approval in DLBCL

Shots: Tahi and Asud initiated the conversation with an overview of EPKINLYTM (epcoritamab) and its approval by the U.S. FDA to treat R/R DLBCL They then spoke about the study design and results from the EPCORE NHL-1 P-I/II trial that served as the basis for the U.S. FDA approval of EPKINLY. EPKINLY is being co-developed and co-commercialized by Genmab and AbbVie. Both companies are evaluating…
August 2, 2023

Read more